The Motley Fool
06 Nov 2026, 14:48 UTC · 58m ago
Moderna Just Gave Investors Yet Another Thing to Cheer About
Impact · against what's priced in
Moderna's surprise return to profitability and raised guidance provide a positive catalyst by improving the balance sheet durability and current franchise performance, which were previously under pressure. The melanoma vaccine news is largely priced in, but the shift in financial stability reduces the risk of cash-burn-driven dilution.
- MRNA+0.40
Challenges what's priced in
- The price assumes
the company burns through cash
The market was concerned about cash burn and balance sheet durability; however, a surprise Q3 profit of $162 million and a projected year-end cash balance of $8.1B to $8.3B (up from $4.7B to $5.2B) significantly mitigate this risk.
What MRNA's price assumes · Sep 11
